Targeting metabolic synthetic lethality in cancer research

In this webinar, Dr. Yuting Sun discusses her research supporting a Phase 1 clinical trial advancing cancer therapies, targeted at metabolic vulnerabilities. Metabolic rewiring is a hallmark of cancer. However, the plasticity of preexisting regulatory circuit compromises the effectiveness of targeted therapies. We postulate that leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. In this presentation, we discuss strategies in targeting two distinct metabolic vulnerabilities- FHmut cancer and glycolysis-deficient cancer.

In this webinar we will discuss:

  • Targeting redox balance in FHmut cancer.
  • Targeting OXPHOS in glycolysis deficient tumor.
  • Utilization of seahorse assay supporting Phase 1 clinical trial (for research use).

Wednesday, July 17, 2019

08:00 PDT (Los Angeles)
11:00 EDT (New York)
16:00 GMT (London)

Presented by:

Yuting Sun, PhD
Institute Research Scientist
MD Anderson Cancer Center

  Register now  

For Research Use Only. Not for use in diagnostic procedures.

©2018 Agilent Technologies